0000950170-23-048440.txt : 20230915 0000950170-23-048440.hdr.sgml : 20230915 20230915174727 ACCESSION NUMBER: 0000950170-23-048440 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230913 FILED AS OF DATE: 20230915 DATE AS OF CHANGE: 20230915 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HAMED KAMAL CENTRAL INDEX KEY: 0001946366 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38266 FILM NUMBER: 231259669 MAIL ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spero Therapeutics, Inc. CENTRAL INDEX KEY: 0001701108 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-242-1600 MAIL ADDRESS: STREET 1: 675 MASSACHUSETTS AVENUE STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Spero Therapeutics, LLC DATE OF NAME CHANGE: 20170316 4 1 ownership.xml 4 X0508 4 2023-09-13 0001701108 Spero Therapeutics, Inc. SPRO 0001946366 HAMED KAMAL C/O SPERO THERAPEUTICS, INC. 675 MASSACHUSETTS AVENUE, 14TH FLOOR CAMBRIDGE MA 02139 false true false false Chief Medical Officer false Common Stock 2023-09-13 4 S false 39496 1.27 D 576461 D The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of (i) restricted stock units ("RSUs") that were granted to the Reporting Person on September 12, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement and (ii) performance-based restricted stock units ("PSUs") that were granted to the Reporting Person on August 4, 2022, subject to the achievement of certain pre-established performance criteria, which the Board of Directors of the Issuer determined had been 100% met on June 12, 2023, pursuant to a "sell to cover" provision included in the PSU Agreement. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.27 to $1.295 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. /s/ Tamara Joseph, Attorney-in-Fact for Kamal Hamed 2023-09-15